ImageneBio, Inc. Income Statement
IMA|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
ImageneBio, Inc. reported $4M in revenue and $37M in net loss for FY2025. Revenue has declined at a 21.5% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.5M | $9.2M | $15.6M | $31.0M | $9.2M |
| SG&A Expense | $8.4M | $24.9M | $22.2M | $18.0M | $8.9M |
| R&D Expense | $32.1M | $59.7M | $64.3M | $47.1M | $44.8M |
| Operating Income | -$37.0M | -$75.4M | -$70.9M | -$34.1M | -$44.5M |
| Income Tax | $13.0K | -$162.0K | -$162.0K | $0 | $0 |
| Net Income | -$36.6M | -$68.2M | -$68.8M | -$34.1M | -$44.3M |
| EPS (Basic) | -$22.10 | -$1.63 | -$1.90 | -$1.22 | - |
| EPS (Diluted) | -$22.10 | -$1.63 | -$1.90 | -$1.22 | -$16.00 |
| Shares Outstanding | - | 48.3M | 36.3M | 36.0M | 3.1M |
| Operating Margin | -1057.1% | -823.3% | -454.0% | -110.2% | -484.2% |
| Profit Margin | -1044.8% | -744.2% | -440.3% | -110.1% | -481.4% |